Skip to main content
TipRanks
Go Ultimate75% OFF

Latigo Biotherapeutics, Inc. (LTGO) Stock Statistics & Valuation Metrics

40 Followers

Total Valuation

Latigo Biotherapeutics, Inc. has a market cap or net worth of $912.28M. The enterprise value is $706.98M.

Market Cap
$912.28M
Enterprise Value
$706.98M

Share Statistics

Latigo Biotherapeutics, Inc. has 66,299,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
66,299,350
Owned by Insiders
28.68%
Owned by Institutions
54.66%

Financial Efficiency

Latigo Biotherapeutics, Inc.’s return on equity (ROE) is 0.47 and return on invested capital (ROIC) is -191.54%.

Return on Equity (ROE)
0.47
Return on Assets (ROA)
-1.45
Return on Invested Capital (ROIC)
-191.54%
Return on Capital Employed (ROCE)
-1.93
Revenue Per Employee
0
Profits Per Employee
-1.65M
Employee Count
66
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Latigo Biotherapeutics, Inc. is -9.18. Latigo Biotherapeutics, Inc.’s PEG ratio is 0.10.

PE Ratio
-9.18
PS Ratio
0.00
PB Ratio
1.32
Price to FCF
-8.05
Price to Operating Cash Flow
-5.07
PEG Ratio
0.10

Income Statement

In the last 12 months, Latigo Biotherapeutics, Inc. had revenue of 0 and earned -109.17M in profits. Earnings per share was -2.48.

Revenue
0
Gross Profit
0
Operating Income
-110.39M
Pretax Income
-109.17M
Net Income
-109.17M
EBITDA
-110.14M
Earnings Per Share (EPS)
-2.48

Cash Flow

In the last 12 months, operating cash flow was -102.80M and capital expenditures -147,000, giving a free cash flow of -102.95M billion.

Operating Cash Flow
-102.80M
Free Cash Flow
-102.95M
Free Cash Flow per Share
-2.72

Dividends & Yields

Latigo Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-12.33%
Earnings Yield
-20.43%

Stock Price Statistics

Beta
0.78
52-Week Price Change
-24.60%
50-Day Moving Average
17.02
200-Day Moving Average
18.29
Relative Strength Index (RSI)
45.45
Average Volume (3m)
307.31K

Important Dates

Latigo Biotherapeutics, Inc. upcoming earnings date is ―, Before Open (Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

Latigo Biotherapeutics, Inc. as a current ratio of 4.00, with Debt / Equity ratio of -0.30%

Current Ratio
4.00
Quick Ratio
4.00
Debt to Market Cap
0.00
Net Debt to EBITDA
0.62
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Latigo Biotherapeutics, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Latigo Biotherapeutics, Inc. EV to EBITDA ratio is -4.03, with an EV/FCF ratio of -4.22.

EV to Sales
0.00
EV to EBITDA
-4.03
EV to Free Cash Flow
-4.22
EV to Operating Cash Flow
-4.23

Balance Sheet

Latigo Biotherapeutics, Inc. has $401.24M in cash and marketable securities with $1.19M in debt, giving a net cash position of $400.05M billion.

Cash & Marketable Securities
$401.24M
Total Debt
$1.19M
Net Cash
$400.05M
Net Cash Per Share
$6.03
Tangible Book Value Per Share
$10.41

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Latigo Biotherapeutics, Inc. is $57.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$57.67
Price Target Upside
319.09% Upside
Analyst Consensus
Strong Buy
Analyst Count
3
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
8
AI Score
―